We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Two Firms Join to Develop Quick Flu Test

By Labmedica staff writers
Posted on 26 Jan 2006
A fast, lab-on-a-chip diagnostic test that will enable doctors to quickly detect strains of avian flue and other influenza viruses is being developed by STMicroelectronics (Geneva, Switzerland) and Veredus Laboratories (Singapore).

Using the In-Check platform of ST, Veredus is working on an application to specifically identify whether a patient is infected with the avian flu virus H5N1 or a subtype of influenza A or B in a single test, instead of requiring many tests. More...
The companies hope to have the test available for the next flu season in the fall of 2006. The In-Check platform is a complete laboratory-on-a-chip. It allows users to accurately and reliably perform the processing and analysis of a minute sample on a single disposable chip, and also reduces the risk of cross-contamination. The results are detected by a portable reader using optical signal acquisition and processed by ST's bioinformatics software.

"The World Health Organization recently identified rapid detection as the first requirement in fighting avian flu, and ST's leading-edge semiconductor expertise--combined with Veredus' expertise in avian flu detection--will enable new possibilities for effective timely detection and treatment so that early containment of the infection will be possible,” said Anton Hofmeister, group vice-president and general manager for ST's microfluidic division.

"We are actively developing chips to detect dengue fever, malaria, West Nile virus, yellow fever, typhoid fever, Japanese encephalitis, and other diseases and anticipate that our products will greatly improve treatment choices,” added Dr. Rosemary Tan, CEO of Veredus.




Related Links:
STMicroelectronics
Veredus Laboratories

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.